NAFTA 2.0: Obstacles to More Affordable Medicines | Association for Accessible Medicines

NAFTA 2.0: Obstacles to More Affordable Medicines

NAFTA 2.0 (USMCA) will keep drug prices out of reach for American patients.

Patients in the U.S. are already confronted by the world’s longest climb to affordable biosimilar medicines. NAFTA 2.0 (USMCA) will eliminate easier routes and keeps drug prices out of reach for American patients.

The U.S.-Mexico-Canada Agreement (USMCA), the update to the North America Free Trade Agreement (NAFTA), contains provisions that will: 

  1. Increase the cost of medicines in the United States;
  2. Extend monopolies for the most expensive drugs in the market; and
  3. Disincentivize the development of less expensive generic and biologic drugs that are the key to driving down drug costs.
USMCA Infographic

Download Infographic

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.